ArticleTheranostics2021

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.

Danny Feijtel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.